Labcorp shares are trading higher after the company announced that the FDA approved its nABCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic, to determine patient eligibility for treatment with BEQVEZ.

Laboratory Corporation of America Holdings -0.33%

Laboratory Corporation of America Holdings

LH

215.78

-0.33%

Labcorp shares are trading higher after the company announced that the FDA approved its nABCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic, to determine patient eligibility for treatment with BEQVEZ.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via